跳至主要内容
临床试验/NCT01519882
NCT01519882终止4 期

A Multi-Centre, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Effects of Rotigotine on Sleep Efficiency in Patients With Advanced Parkinson's Disease.

UCB Pharma SA1 个研究点 分布在 1 个国家目标入组 1 人开始时间: 2012年3月最近更新:
适应症

试验速览

阶段
4 期
状态
终止
发起方
UCB Pharma SA
入组人数
1
试验地点
1
主要终点
Percentage Change From Baseline in Sleep Efficiency Index (SEI) to Week 4 of the Maintenance Period

研究概览

简要总结

This is a phase 4 study to evaluate with Polysomnography (PSG) and subjective measures the effect of Rotigotine on sleep efficiency, maintenance, insomnia, nocturnal akinesia and night-time movement in bed, in patients with advanced Parkinson's disease.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Advanced Parkinson's disease (ie, takes Levodopa (L-DOPA))
  • Hoehn and Yahr stage score of 2 to 4
  • Subject has sleep-maintenance insomnia

排除标准

  • Significant skin disease that would make transdermal drug use inappropriate
  • Subject received therapy with controlled-release Levodopa (L-DOPA), entacapone or Stalevo® within 28 days prior to the Baseline Visit or has received therapy with Tolcapone
  • Atypical Parkinsonian syndromes
  • Previous diagnosis of Narcolepsy, Sleep Apnoea Syndrome, significant Rapid Eye Movement (REM) Sleep Behavior Disorder (RBD), moderate to severe Restless Legs Syndrome (RLS) or Periodic Limb Movement Disorder

结局指标

主要结局

Percentage Change From Baseline in Sleep Efficiency Index (SEI) to Week 4 of the Maintenance Period

时间窗: From Baseline to Week 4 of the Maintenance Period (up to 11 weeks post-baseline)

The Sleep Efficiency Index in percent is the ratio of total sleep time (based on Polysomnography recordings) to time in bed (period between "lights off" and "lights on").

次要结局

  • Change From Baseline in the Parkinson's Disease Sleep Scale Score Version 2 (PDSS2) to Day 1 of the Maintenance Period(From Baseline to Day 1 of the Maintenance Period (up to 7 weeks post-baseline))
  • Change From Baseline in the Parkinson's Disease Sleep Scale Score Version 2 (PDSS2) to Week 4 of the Maintenance Period(From Baseline to Week 4 of the Maintenance Period (up to 11 weeks post-baseline))
  • Change From Baseline in the Epworth Sleepiness Score (ESS) to Day 1 of the Maintenance Period(From Baseline to Day 1 of the Maintenance Period (up to 7 weeks post-baseline))
  • Change From Baseline in the Epworth Sleepiness Score (ESS) to Week 4 of the Maintenance Period(From Baseline to Week 4 of the Maintenance Period (up to 11 weeks post-baseline))
  • Change From Baseline in the Sleep Period Time in Non-Rapid Eye Movement (Non-REM) Sleep to Week 4 of the Maintenance Period(From Baseline to Week 4 of the Maintenance Period (up to 11 weeks post-baseline))
  • Change From Baseline in the Nocturnal Akinesia, Dystonia, and Cramps Score (NADCS) to Day 1 of the Maintenance Period(From Baseline to Day 1 of the Maintenance Period (up to 7 weeks post-baseline))
  • Change From Baseline in the Nocturnal Akinesia, Dystonia and Cramps Score (NADCS) to Week 4 of the Maintenance Period(From Baseline to Week 4 of the Maintenance Period (up to 11 weeks post-baseline))
  • Change From Baseline in the Total Wake Time After Sleep Onset (WASO) to Week 4 of the Maintenance Period(From Baseline to Week 4 of the Maintenance Period (up to 11 weeks post-baseline))
  • Change From Baseline in the Total Number of Turnings in Bed to Week 4 of the Maintenance Period(From Baseline to Week 4 of the Maintenance Period (up to 11 weeks post-baseline))

研究者

发起方
UCB Pharma SA
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验